argenx SE American Depositary Shares (ARGX)

FairStock Score: 57/100 — STEADY

Key Financials

Strengths

• Generates $513 million in annual free cash flow (1.0% yield on market cap)
• High return on equity of 20.1% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.01, providing financial flexibility
• Altman Z-Score of 23.1 confirms minimal bankruptcy risk and strong solvency
• Healthy net profit margin of 10.7% showing consistent profitability

Concerns

• Trades significantly above Graham Number ($228) with negative 251% margin of safety—limited downside protection
• Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

argenx SE American Depositary Shares is a large-cap healthcare company valued at $50.1 billion. The business generates $4.2 billion in annual revenue with a 10.7% net margin and $513 million in free cash flow. From a quality standpoint, argenx shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and Altman Z-Score of 23.1 confirms fortress-level solvency. On valuation, the stock is commanding a steep 40.2x multiple, with trades far above its Graham Number ($228) with no margin of safety. Growth dynamics show revenue growing at 74.4% and profit growth of -31.2%. Our composite FairStock Score of 51/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

argenx's 74% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $513 million in annual free cash flow (1.0% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

At 40x earnings, any growth disappointment triggers rapid multiple compression—a 20% earnings miss plus multiple contraction to 20x implies 40%+ downside. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer